Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 986 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard of Care Placebo Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction and Creatine Supplementation in Women

NCT05877417
View directory record Official record
Conditions
Physical Inactivity
Interventions
Creatine Monohydrate, Blood Flow Restriction, Exercise
Dietary Supplement · Device · Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

NCT01134510
View directory record Official record
Conditions
Kidney Transplantation
Interventions
C1 Esterase Inhibitor, Placebos
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 24, 2026, 2:08 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort

NCT02668510
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
platelet rich plasma, Normal saline
Biological · Drug
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 24, 2026, 2:08 AM EDT
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

NCT04560998
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 24, 2026, 2:08 AM EDT
Recruiting Phase 4 Interventional

The Mechanism Versus PPI Trial

NCT06999577
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Cough, Throat Clearing, Dysphonia, Reflux
Interventions
Omeprazole 40 MG, Laryngeal Recalibration Therapy, GERD Lifestyle Recommendations
Drug · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Deigo, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Not applicable Interventional Results available

Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery

NCT00840996
View directory record Official record
Conditions
Spine Surgery
Interventions
Lidocaine, placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 24, 2026, 2:08 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction Therapy in Lower Limb Extensor Injuries

NCT04149977
View directory record Official record
Conditions
Lower Limb Injury
Interventions
Physical Therapy with pressure cuff, Physical Therapy with placebo pressure cuff
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 24, 2026, 2:08 AM EDT
Not yet recruiting Not applicable Interventional

Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer

NCT07406594
View directory record Official record
Conditions
Breast Cancer, HER-2 Positive Breast Cancer
Interventions
Resistant Potato Starch, Placebo control
Dietary Supplement
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With COVID-19

NCT04421027
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Not applicable Interventional

Aromatherapy Effect on Anxiety Prior to Ultrasound Guided Musculoskeletal Procedures

NCT05660486
View directory record Official record
Conditions
Anxiety State
Interventions
Aromatherapy, Placebo
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitrous Oxide for Pain Management of First Trimester Surgical Abortion

NCT02096575
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Nitrous oxide administration
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

NCT04583592
View directory record Official record
Conditions
COVID-19
Interventions
Camostat Mesilate, Placebo
Drug
Lead sponsor
Sagent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Palm Springs, California • Bradenton, Florida • Brandon, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 24, 2026, 2:08 AM EDT
Not yet recruiting Phase 2 Interventional

Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing

NCT07384767
View directory record Official record
Conditions
Mohs Micrographic Surgery, Excision Margin
Interventions
Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 24, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Filgotinib, Placebo, Standard of Care
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 10 mg/kg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 24, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

NCT03773172
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
MEDI6012, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

COVID-19 Study of Safety and Tolerability of Alvelestat

NCT04539795
View directory record Official record
Conditions
Covid19
Interventions
Alvelestat, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 24, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03226392
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Andalusia, Alabama • Birmingham, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 24, 2026, 2:08 AM EDT